Clinical Trial

Intrathecal Double Checkpoint Inhibition

Study acronym: IT-IO
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-10-26; most recent amendment 2025-09-28.
Status change: Recruiting → Active, Not Recruiting 2025-09-28
Status change: Not Yet Recruiting → Recruiting 2022-12-08
Trial Details
NCT Number NCT05598853
Lead Sponsor University of Zurich
Conditions Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
Enrollment 26 participants
Start Date 2022-11-25
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-02